Ip6k3 is upregulated in NAFLD patients [231], whereas Ip6k1 and Ip6k2 expression directly correlate with hepatocellular carcinoma (HCC) [230]. Here, IP6K1 is linked to metabolic dysfunction-associated steatotic liver disease.